title: Alterations in eotaxin, monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 after systemic steroid treatment for nasal polyps.
abstract: OBJECTIVE
  To determine alterations in Th2 chemokines eotaxin and monocyte chemoattractant protein-4 (MCP-4), and cytokines interleukin-5 (IL-5) and interleukin-13 (IL-13), in nasal polyps (NP) after steroid treatment.
  
  
  METHODS
  Cytokine/chemokine levels were measured in NP before and after steroid therapy and compared to control sinus mucosa.
  
  
  RESULTS
  Twenty-one patients (control = 7, NP = 14) were enrolled. Eotaxin and MCP-4 were significantly higher than control tissue (P = 0.004 and 0.003). All four mediators decreased after steroid treatment (P < 0.03). IL-5 and IL-13 in untreated polyps were not significantly different from controls. Patients showed clinical improvement according to SNOT-20 scores (average presteroid score 19, poststeroid score 13) and endoscopic grading (1.75 each side presteroid, 1.13 poststeroid).
  
  
  CONCLUSIONS
  Steroids significantly decreased all cytokine/chemokine levels, but the impact on Th2 chemokines was of a much greater magnitude.
  
  
  CONCLUSIONS
  Novel approaches to block inflammatory mediators, particularly Th2 chemokines, may lead to better control of nasal polyposis in the future.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Bradford A
authors.initials: BA
authors.lastname: Woodworth
authors.forename: Kusumam
authors.initials: K
authors.lastname: Joseph
authors.forename: Allen P
authors.initials: AP
authors.lastname: Kaplan
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Schlosser
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000276:immunology; D004724:Endoscopy; D005260:Female; D006801:Humans; D018793:Interleukin-13 / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology; D008297:Male; D018945:Monocyte Chemoattractant Proteins / Q000276:immunology; D009298:Nasal Polyps / Q000188:drug therapy / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use*; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; C515456:CCL11 protein, human; C099677:CCL13 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D018793:Interleukin-13; D015848:Interleukin-5; D018945:Monocyte Chemoattractant Proteins; D011241:Prednisone